Principia Biopharma (NASDAQ: PRNB) is one of 546 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Principia Biopharma to similar businesses based on the strength of its institutional ownership, analyst recommendations, profitability, risk, dividends, valuation and earnings.
Insider & Institutional Ownership
81.9% of Principia Biopharma shares are owned by institutional investors. Comparatively, 46.6% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 14.8% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Principia Biopharma and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Principia Biopharma Competitors||-1,776.08%||-105.48%||-28.48%|
This is a breakdown of current recommendations for Principia Biopharma and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Principia Biopharma Competitors||4499||12939||27592||991||2.54|
Principia Biopharma currently has a consensus target price of $42.00, indicating a potential upside of 51.02%. As a group, “Pharmaceutical preparations” companies have a potential upside of 52.51%. Given Principia Biopharma’s competitors higher possible upside, analysts plainly believe Principia Biopharma has less favorable growth aspects than its competitors.
Earnings and Valuation
This table compares Principia Biopharma and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Principia Biopharma||$69.14 million||$18.17 million||48.79|
|Principia Biopharma Competitors||$2.17 billion||$229.91 million||-3.77|
Principia Biopharma’s competitors have higher revenue and earnings than Principia Biopharma. Principia Biopharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Principia Biopharma beats its competitors on 7 of the 12 factors compared.
About Principia Biopharma
Principia Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has collaboration agreements with Genzyme Corporation and AbbVie Biotechnology Limited. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
Receive News & Ratings for Principia Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Principia Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.